GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » American Cryostem Corp (OTCPK:CRYO) » Definitions » Net Change in Cash

American Cryostem (American Cryostem) Net Change in Cash : $-0.01 Mil (TTM As of Jun. 2022)


View and export this data going back to 2010. Start your Free Trial

What is American Cryostem Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

American Cryostem's Net Change in Cash for the three months ended in Jun. 2022 was $-0.02 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2022 was $-0.01 Mil.

American Cryostem Net Change in Cash Historical Data

The historical data trend for American Cryostem's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

American Cryostem Net Change in Cash Chart

American Cryostem Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.37 -0.34 -0.05 0.02 -0.03

American Cryostem Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.10 - 0.10 -0.08 -0.02

American Cryostem Net Change in Cash Calculation

American Cryostem's Net Change in Cash for the fiscal year that ended in Sep. 2021 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-0.304+-0.091+0.362+0
=-0.03

American Cryostem's Net Change in Cash for the quarter that ended in Jun. 2022

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-0.123+-0.024+0.127+0
=-0.02

Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

American Cryostem Net Change in Cash Related Terms

Thank you for viewing the detailed overview of American Cryostem's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

American Cryostem (American Cryostem) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » American Cryostem Corp (OTCPK:CRYO) » Definitions » Net Change in Cash
Comparable Companies
ARTH HOTH ARTL PTIX SILO IPIX WINT GLMD LOGC XCUR OCSE:NOVO B ASX:CSL REGN VRTX MRNA XKRX:207940 BNTX HKSE:02269 SGEN SZSE:300122
Traded in Other Exchanges
N/A
Address
1 Meridian Road, Suite 5, Eatontown, NJ, USA, 07724
Website
http://www.americancryostem.com
American Cryostem Corp is a biotechnology company which standardizes adipose tissue-derived technologies (Adult Stem Cells) for the fields of Regenerative and Personalized Medicine. The company acts as an innovator of adipose tissue and stem cell platform technologies. It provides the clinical grade, adipose tissue and adult stem cell collection, processing, and cryo-preservation technology, providing first-in-class cellular therapy products and services for patients, physicians and researchers based on the transformative science of Regenerative and Personalized Medicine.
Executives
John S Arnone director, officer: Chairman 111 GREAT NECK RD, GREAT NECK NY 11021
Anthony Francis Dudzinski director, officer: COO 188 EAST BERGEN PLACE, SUITE 204, RED BANK NJ 07701
Acs Global, Inc. 10 percent owner 188 E. BERGEN PLACE, SUITE 204, RED BANK NJ 07701
Christopher Joseph Neill 10 percent owner 188 EAST BERGEN PLACE, SUITE 204, RED BANK NJ 07701
Hector Medina director, 10 percent owner, officer: President and Director 1206 STAGECOACH TRAIL LOOP, CHULA VISTA CA 91915